Systemic therapy breakthroughs in the management of brain metastases: A new era for HER2-positive breast cancer

作者
Martina Parenza Arenhardt,Carolina Martins Vieira,Angélica Nogueira‐Rodrigues
出处
期刊:Cancer treatment and research communications [Elsevier BV]
卷期号:45: 100997-100997 被引量:1
标识
DOI:10.1016/j.ctarc.2025.100997
摘要

HER2-positive subtype accounts for 15-20 % of metastatic breast cancer (mBC) cases and is associated with a high incidence of brain metastases (BMs), which affects 35-50 % of the patients, contributing to poor outcomes. Although HER2-targeted therapies have significantly improved overall survival (OS), central nervous system (CNS) involvement remains a significant challenge due to the blood-brain barrier (BBB), which limits systemic treatment efficacy. The advent of antibody-drug conjugates (ADCs) has introduced promising therapeutic options with demonstrated CNS activity. This narrative review synthesizes current evidence on systemic treatments for HER2-positive BMs. A comprehensive literature search included PubMed, ASCO, ESMO, and NCCN guidelines, as well as ongoing trials from ClinicalTrials.gov. Until recently, the HER2CLIMB regimen-combining tucatinib, trastuzumab, and capecitabine-was the most effective option for CNS disease control, achieving a median CNS progression-free survival (PFS) of 9.9 months. However, recent trials highlight the transformative impact of antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), in this clinical setting. Pooled analyses from the DESTINY-Breast trials reported intracranial overall response rates (ICORR) of 45.5 % in untreated and 45.2 % in treated BMs. Smaller studies, such as DEBBRA and TUXEDO-1, demonstrated ICORRs of 66.7 % and 73.3 %, respectively, with TUXEDO-1 reporting a median PFS of 14 months. The phase III/IV DESTINY-Breast12 trial further validated T-DXd's efficacy in active BMs, achieving a CNS PFS of 17.3 months and an ICORR of 62.3 %, with the highest responses (82.6 %) in untreated BMs. The current analysis reviews the available data on managing brain metastasis and highlights T-DXd's potential to redefine treatment strategies. It also discusses unanswered questions, such as the role of radiotherapy in asymptomatic disease and the evolving landscape of ADCs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
赘婿的应助被fcc采纳,获得10
1秒前
1秒前
周彬超发布了新的文献求助10
1秒前
nha完成签到,获得积分10
2秒前
乐正天与发布了新的文献求助10
2秒前
2秒前
alan完成签到,获得积分10
2秒前
MichaelQiang的应助被虚拟的画板采纳,获得10
2秒前
要吃虾饺发布了新的文献求助10
2秒前
大呲花发布了新的文献求助10
2秒前
Nora发布了新的文献求助10
3秒前
惊蛰发布了新的文献求助10
3秒前
香蕉觅云的应助被lcj1014采纳,获得10
3秒前
英俊的铭的应助被陈俊瑶采纳,获得10
3秒前
CodeCraft的应助被fcc采纳,获得10
3秒前
abc37发布了新的文献求助10
4秒前
zhang发布了新的文献求助10
5秒前
5秒前
5秒前
战火完成签到 ,获得积分10
5秒前
完美世界的应助被畅快远山采纳,获得30
5秒前
6秒前
传奇3的应助被fcc采纳,获得10
6秒前
6秒前
CipherSage的应助被学术大佬采纳,获得10
6秒前
123完成签到,获得积分10
6秒前
6秒前
cranberry完成签到,获得积分10
7秒前
7秒前
Yang完成签到,获得积分10
7秒前
叶凡发布了新的文献求助10
7秒前
7秒前
东方欲晓发布了新的文献求助50
7秒前
7秒前
共享精神的应助被杨好圆采纳,获得30
7秒前
8秒前
MMM驳回了彭于晏的应助
8秒前
华仔的应助被fcc采纳,获得10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170142
求助须知:如何正确求助?哪些是违规求助? 9563136
关于积分的说明 21768635
捐赠科研通 7761603
什么是DOI,文献DOI怎么找? 3430600
关于科研通互助平台的介绍 2554420
邀请新用户注册赠送积分活动 2475330